Comparative Pharmacology
Head-to-head clinical analysis: PAVULON versus SYNCURINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAVULON versus SYNCURINE.
PAVULON vs SYNCURINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing skeletal muscle paralysis.
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
0.1-0.2 mg/kg IV bolus for paralysis, repeat 0.05-0.1 mg/kg as needed; maintenance infusion 0.5-1.5 mcg/kg/min IV.
None Documented
None Documented
Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment.
Terminal half-life: 2-5 hours (prolonged with renal impairment; up to 10 hours in severe impairment)
Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%).
Primarily renal excretion (50-70% unchanged drug), with biliary/fecal elimination (10-20%)
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent